Russia’s coronavirus vaccine remarks ‘unethical’: RDIF chief

According to Kirill Dimitriev, chief executive of Russia’s Sovereign Wealth Fund RDIF – “Sputnik V.” Russia’s criticism of the coronavirus vaccine, which supports the controversial name vaccine, is unhealthy, unethical and unproductive.

“We are completely transparent and open. There is a very negative story in some western countries, and clearly we think it’s very sad because basically they can’t keep people honest about our vaccine,” Dimitriev told CNBC’s Capital. “Connection” on Tuesday.

“We all need to stop this rhetoric from being too pragmatic and trying to blacken each other’s vaccines. It’s too healthy, it’s too unethical and too unproductive.”

Russian President Vladimir Putin claimed in August that his country had registered the world’s first vaccine for coronavirus, or Covid-19.

We are facing the worst epidemic ever and I think countries need to be pragmatic. Try different vaccines, and don’t rely on just one …

Kirill Dimitriev


The announcement immediately drew the attention of scientists and public health officials. They questioned the safety and effectiveness of the vaccine as it had yet to undergo further comprehensive Phase 3 clinical trials and pointed out. Data from previous tests

Not republished.

Last month, a study published in the peer-reviewed medical journal The Lancet said that preliminary results from Russian tests showed no serious negative side effects in the vaccine. However, some scientists have questioned the reliability of the data in the study.

However, two countries – Belarus and the United Arab Emirates – have launched human tests for the Russian vaccine. Additional trials are set to begin in Venezuela, according to the report.

Dmitryv said countries should “test for themselves” the safety and effectiveness of Russia’s vaccines.

“We are dealing with the worst epidemic ever and I think countries need to be pragmatic,” he said. “Try different vaccines, and don’t just rely on one vaccine, but put multiple vaccines in the portfolio.”